ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

イミプラミン塩酸塩

Imipramine Hydrochloride

HCID 8228
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
113-52-0
標準SMILES
CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl
InChIKey
XZZXIYZZBJDEEP-UHFFFAOYSA-N
分子式
C19H25ClN2
平均分子量
316.9 g/mol
単同位体質量
316.1706265

概要

Imipramine Hydrochloride is the hydrochloride salt form of imipramine, a synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)

名称と識別子

優先名称
Imipramine Hydrochloride
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride
現地名
イミプラミン塩酸塩
英語名
Imipramine hydrochloride
分子式
C19H25ClN2
分子量
316.87

名称と別名

Imipramine hydrochloride113-52-0Imipramine HclTofranilPresaminePryleuganPramineAntideprin hydrochlorideImipramini hydrochloridumPraminilSarimpDTXSID7040738
名称をさらに表示
テペリントフラニルイミジンイミドールトフラニールN,N-ジメチル-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン-5-(プロパン-1-アミン)·塩酸塩イミプラミン塩酸塩塩酸イミプラミンメリプラミン塩酸塩10,11-ジヒドロ-N,N-ジメチル-5H-ジベンゾ[b,f]アゼピン-5-プロパン-1-アミン·塩酸塩アンチデプリン塩酸塩5-[3-(ジメチルアミノ)プロピル]-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン·塩酸塩10,11-ジヒドロ-N,N-ジメチル-5H-ジベンゾ[b,f]アゼピン-5-プロパンアミン塩酸塩5-[3-(ジメチルアミノ)プロピル]-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン塩酸塩イミプラミン 塩酸塩イミプラミン 塩酸塩 溶液イミプラミン塩酸塩 (JP17)g22355imidolia-pramimavateiprogendeprinoldynazinaefuranol
BKE5Q1J60UNSC-114900G-223555H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochlorideCHEBI:5882DTXCID5020738NSC1149005H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride

データベース識別子

CAS
113-52-0
PubChem CID
8228
DTXSID
DTXSID7040738
ChEMBL
CHEMBL1692
UNII
BKE5Q1J60U
EC Number
204-030-7

物性

構造計算による物性

極性表面積
6.5 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
4
重原子数
22
形式電荷
0
複雑度
291

実験および物理化学的性質

Solubility>47.5 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section165.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
168 · 168-1700C
闪点
9 ℃ · 9℃
貯蔵温度
2 · 2-8°C
溶解性
2 O: · H2O: 50 mg/mL
外見
結晶性
色
白い
PH
4.2 · 4.2~5.2(100g/l,25℃)
水溶解度
水に溶ける
Merck
14 · 14,4920
InChI
1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H
InChIKey
XZZXIYZZBJDEEP-UHFFFAOYSA-N
SMILES
Cl[H].CN(C)CCCN1c2ccccc2CCc3ccccc13
CAS データベース
113 · 113-52-0(CAS DataBase Reference)
EPAの化学物質情報
5 H-Dibenz[b,f]azepine-5-propanamine, · 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride (113-52-0)

化学的性質

化学的特性White Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 92 reports by companies from 4 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationImipramine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Treatment · 1 件

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at anytime during this period, extended monitoring is required. (L1712)

Exposure RoutesRapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.
Toxicity Summary · 1 件

Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.

Signs and Symptoms · 1 件

Antagonism of the histamine H<sub>1</sub> and &alpha;<sub>1</sub> receptors can lead to sedation and hypotension. Antimuscarinic and anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of imipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Imipramine hydrochloride

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 355 to 682 mg/kg (oral, rat).

安全データ

wgk
3
tsca
TSCA listed
rtecs
HO1925000
ridadr
UN 1230 3/PG 2
毒性
LD50 in mice, rats (mg/kg): 400, 490 orally; 110, 90 i.p. (Tobe)
hs_code
2933995800
risk_code
23/25-36/38-36/37/38-22-39/23/24/25-23/24/25-11
hazard_code
Xn,T,F
safety_code
7-16-24-33-45-36-26-36/37
Hazard Classifications
Acute Tox. 2 Oral
ストレージクラス
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Exclusively metabolized by the liver. Imipramine is converted in the liver by various CYP isoenzymes (e.g. CYP1A2, CYP2D6, CYP3A4, CYP2C9) to active metabolites desipramine and 2-hydroxydesipramine. Route of Elimination: Approximately 40% of an orally administered dose is eliminated in urine within 24 hours, 70% in 72 hours. Small amounts are eliminated in feces via the biliary elimination. Half Life: Imipramine - 8-20 hours; Desipramine (active metabolite) - up to 125 hours

FDA Pharmacological Classification · 2 件

IMIPRAMINE HYDROCHLORIDE

Tricyclic Antidepressant [EPC]

MeSH Pharmacological Classification · 2 件

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

用途と製造

Uses · 1 件

For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.

General Manufacturing Information5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, hydrochloride (1:1): ACTIVE
応用分野 · 4 件

用途三環系抗うつ作用化合物です。 モノアミン神経伝達物質再取り込み阻害作用 を示します。

用途三環系抗うつ作用化合物です。 モノアミン神経伝達物質再取り込み阻害作用 を示します。

使用Imipramine hydrochloride is used as a serotonin uptake inhibitor. It mainly used in the treatment of major depression and enuresis (inability to control urination). It has also been evaluated for use in panic disorder.

一般的な説明Imipramine hydrochloride, 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride(Tofranil), is the lead compound of the TCAs. It is also a closerelative of the antipsychotic phenothiazines (replace the10–11 bridge with sulfur, and the compound is the antipsychoticagent promazine). It has weaker D2 postsynaptic blockingactivity than promazine and mainly affects amines (5-HT,NE, and DA) via the transporters. As is typical of dimethylaminocompounds, anticholinergic and sedative (central H1block) effects tend to be marked. The compound per se has a tendency toward a high 5-HT-to-NE uptake block ratio andprobably can be called a serotonin transport inhibitor(SERTI). Metabolic inactivation proceeds mainly by oxidativehydroxylation in the 2-position, followed by conjugationwith glucuronic acid of the conjugate. Urinary excretion predominates(about 75%), but some biliary excretion (up to25%) can occur, probably because of the large nonpolargrouping. Oxidative hydroxylation is not as rapid or completeas that of the more nucleophilic ring phenothiazine antipsychotics;consequently, appreciable N-demethylation occurs,with a buildup of norimipramine (or desimipramine).

上流・下流製品情報

上流原料

Diphenylイミプラミンヘキサメチレンイミンナトリウムアミド塩酸10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン

関連反応

11 件
反応記録を作成
HRID 335046 の反応式
HRID 335046反応物として
HRID 536784 の反応式
HRID 536784反応物として
HRID 536785 の反応式
HRID 536785反応物として
HRID 1484197 の反応式
HRID 1484197反応物として
HRID 1484198 の反応式
HRID 1484198反応物として
HRID 1664118 の反応式
HRID 1664118生成物として反応物として
HRID 2035404 の反応式
HRID 2035404反応物として
HRID 2035405 の反応式
HRID 2035405反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート